Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Cash from Investing Activities (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Cash from Investing Activities for 7 consecutive years, with -$50000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Cash from Investing Activities fell 100.35% year-over-year to -$50000.0, compared with a TTM value of -$83000.0 through Dec 2019, up 98.79%, and an annual FY2024 reading of -$85.4 million, down 356.01% over the prior year.
  • Cash from Investing Activities was -$50000.0 for Q4 2019 at Larimar Therapeutics, up from -$840000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $18.0 million in Q1 2018 and bottomed at -$69.7 million in Q1 2015.
  • Average Cash from Investing Activities over 5 years is -$630210.5, with a median of $8.3 million recorded in 2018.
  • The sharpest move saw Cash from Investing Activities tumbled 1394480.0% in 2015, then skyrocketed 266.15% in 2017.
  • Year by year, Cash from Investing Activities stood at $15.5 million in 2015, then increased by 9.4% to $16.9 million in 2016, then fell by 24.97% to $12.7 million in 2017, then rose by 12.43% to $14.3 million in 2018, then tumbled by 100.35% to -$50000.0 in 2019.
  • Business Quant data shows Cash from Investing Activities for LRMR at -$50000.0 in Q4 2019, -$840000.0 in Q2 2019, and $807000.0 in Q1 2019.